On A Roll: Gilead's Top-Line Quad Data Stack Up To Atripla
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing FDA approval of a new HIV combination last week, Gilead released positive comparative data on the Quad pill Aug. 15.
You may also be interested in...
Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera
Company is pursuing priority review, eyes FDA approval in mid-2012. If Quad is cleared, newly approved Complera will take back seat.
In HIV Research, A Race For The Cure Is Back On Track
Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.
Gilead Complera Launch Imminent Following FDA Approval
Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.